摘要
目的探讨参芪抑瘤方联合放疗对中晚期宫颈癌患者免疫功能及预后的影响。方法选取2015年4月至2018年10月赣州市肿瘤医院收治的84例中晚期宫颈癌患者作为研究对象,按照随机数字表法分为对照组(42例)与观察组(42例)。对照组采用放疗治疗,观察组采用参芪抑瘤方联合放疗治疗。比较两组的疾病控制率、客观缓解率、免疫功能及预后情况。结果观察组患者的客观缓解率为71.43%,高于对照组的47.62%,观察组的疾病控制率为90.48%,高于对照组的69.05%,差异有统计学意义(P<0.05)。观察组治疗后CD3^(+)、CD4^(+)、自然杀伤(NK)细胞水平高于对照组,差异有统计学意义(P<0.05)。观察组的3年生存率高于对照组,肿瘤转移总发生率低于对照组,差异有统计学意义(P<0.05)。结论参芪抑瘤方联合放疗治疗中晚期宫颈癌患者,疗效可靠,可改善机体免疫功能,降低肿瘤转移总发生率,提高3年生存率。
Objective To explore the effect of Shenqi Yiliu Formula combined with radiotherapy on immune function and prognosis of patients with middle and advanced cervical cancer.Methods A total of 84 patients with advanced cervical cancer treated in Ganzhou Cancer Hospital from April 2015 to October 2018 were selected as the research subjects.According to random number table method,they were divided into control group(42 cases)and observation group(42 cases).The control group was treated with radiotherapy,and the observation group was treated with Shenqi Yiliu Formula combined with radiotherapy.The disease control rate,objective remission rate,immune function and prognosis were compared between the two groups.Results The objective remission rate of the observation group was 71.43%,higher than 47.62%of the control group,and the disease control rate of the observation group was 90.48%,higher than 69.05%of the control group,the differences were statistically significant(P<0.05).After treatment,CD3^(+),CD4^(+)and natural killer(NK)cells in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).The 3-year survival rate of the observation group was higher than that of the control group,and the overall incidence of tumor metastasis was lower than that of the control group,the differences were statistically significant(P<0.05).Conclusion Shenqi Yiliu Formula combined with radiotherapy has reliable efficacy in the treatment of patients with middle and advanced cervical cancer,which can improve immune function,reduce the total incidence of tumor metastasis and improve the 3-year survival rate.
作者
黄春兰
洪慧勤
孙颖芳
曾俊琳
袁丽
邹称秀
李美丽
HUANG Chunlan;HONG Huiqin;SUN Yingfang;ZENG Junlin;YUAN Li;ZOU Chengxiu;LI Meili(Department of Radiotherapy,Ganzhou Cancer Hospital,Jiangxi Province,Ganzhou 341000,China;Department of Emergency,the First Affiliated Hospital of Gannan Medical College,Jiangxi Province,Ganzhou 341000,China;Department of Nursing,Hospital of Gannan Normal University,Jiangxi Province,Ganzhou 341000,China;Fuzhou Medical College,Nanchang University,Jiangxi Province,Fuzhou 344000,China)
出处
《中国当代医药》
CAS
2022年第20期88-91,共4页
China Modern Medicine
基金
江西省中医药管理局科技计划课题(2021B164)。
关键词
参芪抑瘤方
放疗
中晚期
宫颈癌
免疫功能
预后
疗效
Shenqi Yiliu Formula
Radiotherapy
Middle and advanced
Cervical cancer
Immune function
Prognosis
Curative effect
